National Cancer Institute (NCI)
cancer.govTotal trials
1,150
Capped at 5,000
Active
247
Phase 3
63
Total enrollment
4,271,254
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 241 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed | — | — | — | — | — | 1 | |
| Recombinant Human Papillomavirus Bivalent Vaccine | — | — | — | — | — | 1 | |
| Recombinant Human Papillomavirus Nonavalent Vaccine | — | — | — | — | — | 1 | |
| Nivolumab | — | — | 36 | ||||
| Cyclophosphamide | — | 65 | |||||
| Paclitaxel | — | — | 51 | ||||
| Carboplatin | — | — | 36 | ||||
| Pembrolizumab | — | — | 19 | ||||
| Gemcitabine Hydrochloride | — | — | 32 | ||||
| Prednisone | — | — | 30 | ||||
| Rituximab | — | — | 27 | ||||
| Ipilimumab | — | — | — | 20 | |||
| Olaparib | — | — | — | 15 | |||
| Venetoclax | — | — | — | 13 | |||
| Cisplatin | — | — | 31 | ||||
| Atezolizumab | — | — | — | — | 13 | ||
| Ibrutinib | — | — | — | 10 | |||
| Cytarabine | — | — | 23 | ||||
| vincristine sulfate | — | — | 19 | ||||
| Bevacizumab | — | — | — | 54 | |||
| Lenalidomide | — | — | — | 16 | |||
| doxorubicin hydrochloride | — | — | 28 | ||||
| Melphalan | — | — | — | 10 | |||
| Gemcitabine | — | — | — | 9 | |||
| Dexamethasone | — | — | 15 | ||||
| Entinostat | — | — | 11 | ||||
| Etoposide | — | — | 25 | ||||
| methotrexate | — | — | — | 16 | |||
| Cabozantinib | — | — | — | 5 | |||
| erlotinib hydrochloride | — | — | 22 | ||||
| docetaxel | — | — | 18 | ||||
| Daunorubicin Hydrochloride | — | — | 11 | ||||
| Mercaptopurine | — | — | — | 7 | |||
| cetuximab | — | — | — | 10 | |||
| Vincristine | — | — | — | 10 | |||
| Doxorubicin | — | — | — | 10 | |||
| Cediranib Maleate | — | — | — | — | 9 | ||
| Obinutuzumab | — | — | — | 4 | |||
| Pegylated Liposomal Doxorubicin Hydrochloride | — | — | — | 4 | |||
| Rituximab and Hyaluronidase Human | — | — | — | — | 3 |
201 more active programs hidden
Next readouts
- 2008-07-01
- 2010-11-01
- 2012-12-31
- 2013-01-22
- 2013-02-15
- 2013-09-13
- 2014-04-30
- 2015-01-31
- 2015-05-11
- 2015-06-01
Top conditions
- Unspecified Adult Solid Tumor, Protocol Specific46
- Lymphoma36
- Breast Cancer36
- Prostate Cancer31
- Advanced Malignant Solid Neoplasm30
- Refractory Malignant Solid Neoplasm25
- Recurrent Melanoma23
- Recurrent Small Lymphocytic Lymphoma21
Frequently asked questions about National Cancer Institute (NCI)
- How many clinical trials does National Cancer Institute (NCI) have on ClinicalTrials.gov?
- National Cancer Institute (NCI) is listed as the lead sponsor on 1,150 clinical trials in ClinicalTrials.gov, 247 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Cancer Institute (NCI)'s trials are in Phase 3?
- 63 of National Cancer Institute (NCI)'s trials are in Phase 3, spread across 241 active drug programs.
- What therapeutic areas does National Cancer Institute (NCI) focus on?
- National Cancer Institute (NCI)'s most-studied conditions on ClinicalTrials.gov are Unspecified Adult Solid Tumor, Protocol Specific, Lymphoma, Breast Cancer, Prostate Cancer, Advanced Malignant Solid Neoplasm.
- When are National Cancer Institute (NCI)'s next clinical trial readouts?
- National Cancer Institute (NCI) has 10 upcoming primary-completion readouts tracked here; the soonest is “Decitabine in Treating Patients With Myelofibrosis”, expected around 2008-07-01.